Beijing CHIRAL-TECH pharmaceutical Co.,Ltd.
Beijing CHIRAL-TECH pharmaceutical Co.,Ltd. (abbreviated as CHIRAL-TECH) was established by overseas Chinese talents in Hui Long Sen tech area in Beijing Economic Technology Development Area. R&D and innovation are the driving force of growth of CHIRAL-TECH. The company is a focus hatched innovation enterprise which enjoys double support policies of BDA and Z-PARK. Being a focus hatched innovation enterprise, CHIRAL-TECH is cooperating with Institute of material Medica (IMM), Academy of military medical sciences (AMMS) and Shenyang Pharmaceutical University (SPU) etc., and jointly undertake Nation Key Technology R&D Programs as well as carry out the development of the new chemistry drugs.
CHIRAL-TECH dedicates its energy and talent to R&D and production of the innovation drugs and high-end generic drugs. The main business of CHIRAL-TECH involves in R&D, technology transfer and cooperation of chemical drug synthesis and preparation, sales and manufacturing of APIs and intermediates and impurity profile. CHIRAL-TECH has equipped with precise apparatus like LC-MS、HPLC、UV、GC and general oral dosage form, freeze drier powder injection and liquid injection, high and low temperature reaction kettle for pilot, rotary evaporator and other facilities. The company has already established the production base in Zhejiang and Shandongprovince, and can independently complete the preclinical study, pilot research and production of chemical drugs.
CHIRAL-TECH invested 20 percent of annual revenue in R&D study. And 70% employees are personnel for R&D. Adhering to the concept of “Quality of products derived from the design and continue to develop during the production”, CHIRAL-TECH is committed to providing professional technical service and excellent products. Since the CHIRAL-TECH was found, it has already established good strategic partnership with Yangtze River Medicine group, Xi’an Lijun Pharmaceutical Co., Ltd, North China Pharmaceutical Group Corp etc.
CHIRAL-TECH will continue focus on the R&D of innovation drugs, actively develops high-end generics, APIs and medicinal intermediates. The company will also continue adhering to our business philosophy in the course of steady growth, and strive to become the outstanding representative in domestic industry and competitive enterprise in global pharmaceutical market.